CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 18 enrolled
Drug / intervention
Selpercatinibdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05338515
NCT05338515Phase 1Completed
CompareCT.gov

A Phase I, Single-Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LOXO-292 in Healthy Adult Subjects

Eli Lilly and Company·interventional·Posted Apr 21, 2022·Updated May 18, 2025

In Brief

A Phase 1 clinical trial evaluating Selpercatinib for Healthy. Completed, enrolled 18 participants across 1 site.

Detailed Summary

The main purpose of this study is to determine how safe and how well tolerated selpercatinib is when given as oral doses to healthy participants. The study will also assess how fast selpercatinib gets into the blood stream and how long it takes the body to remove it. The study will last up to about 6 weeks, inclusive of screening period.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesUnited States
CollaboratorsLoxo Oncology, Inc.

Timeline

Phase 1CompletedFinished
20192020202120222023202420252026
First PostedApr 21, 2022
Enrollment StartFeb 12, 2019
Primary CompletionMar 12, 2019
Study CompletionMar 26, 2019
TodayJul 2, 2026
Enrollment to primary: 1 monthPosted 4.2 years ago

Interventions

Selpercatinibdrug

Administered orally.